16511-38-9

Usage

Chemical Properties

White Solid

Uses

Intermediate in the synthesis of protein kinase inhibitors

InChI:InChI=1/C10H9NO2/c12-9-5-6-10(13)11-8-4-2-1-3-7(8)9/h1-4H,5-6H2,(H,11,13)

Upstream product

• 120572-43-2 diethyl ester of succinoylanthranilic acid 
• 4424-80-0 2,3,4,5-tetrahydro-1H-1-benzo[b]azepin-2-one 
• 120572-38-5 4-[(2-ethoxycarbonylphenyl)amino]-4-oxobutanoic acid 
• 134-20-3 2-carbomethoxyaniline 
• 59868-50-7 4-[2-(methoxycarbonyl)anilino]-4-oxobutanoic acid methyl ester 
• 59868-53-0 2,5-dioxo-2,3,4,5-tetrahydro-1H-benz[b]azepine-4-carboxylic acid methyl ester 
• 2942-58-7 diethyl cyanophosphonate 
• 253264-94-7 ethyl 4-(2-aminophenyl)-4-oxobutanoate 
• 130-15-4 [1,4]naphthoquinone 
• 87-25-2 2-ethoxycarbonylaniline 
• 108993-98-2 2,3,-Dihydro-5-hydroxy-2-oxo-1H-1-benzazepin-4-carbonsaeureethylester 
• 10315-38-5 2,5-Dihydro-2,5-dioxobenzazepine 

Downstream Products

• 142273-18-5 paullone 
• 909078-65-5 4-(3-Oxo-1,3-diphenyl-propyl)-3,4-dihydro-1H-benzo[b]azepine-2,5-dione 
• 1026249-57-9 4-[3-(4-Chloro-phenyl)-3-oxo-1-phenyl-propyl]-3,4-dihydro-1H-benzo[b]azepine-2,5-dione 
• 1027245-31-3 4-[1-(4-Bromo-phenyl)-3-oxo-3-phenyl-propyl]-3,4-dihydro-1H-benzo[b]azepine-2,5-dione 
• 1026166-45-9 4-(3-Naphthalen-2-yl-3-oxo-1-phenyl-propyl)-3,4-dihydro-1H-benzo[b]azepine-2,5-dione 
• 1027411-02-4 4-[1-(4-Methoxy-phenyl)-3-oxo-3-phenyl-propyl]-3,4-dihydro-1H-benzo[b]azepine-2,5-dione 
• 357277-67-9 4-[3-(2-furyl)-3-oxo-1-phenyl-propyl]-1H-[1]benzazepine-2,5(3H,4H)-dione 
• 357277-63-5 4-[1-(2-furyl)-3-oxo-3-phenyl-propyl]-1H-[1]benzazepine-2,5(3H,4H)-dione 

Relevant academic research and scientific papers

Fast and calibration free determination of first order reaction kinetics in API synthesis using in-situ ATR-FTIR

In early stages of drug development only sparse amounts of the key substances are available, which is problematic for the determination of important process data like reaction kinetics. Therefore, it is important to perform experiments as economically as

Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of polo-like kinase 1 (MLN0905)

This article describes the discovery of a series of potent inhibitors of Polo-like kinase 1 (PLK1). Optimization of this benzolactam-derived chemical series produced an orally bioavailable inhibitor of PLK1 (12c, MLN0905). In vivo pharmacokinetic-pharmacodynamic experiments demonstrated prolonged mitotic arrest after oral administration of 12c to tumor bearing nude mice. A subsequent efficacy study in nude mice achieved tumor growth inhibition or regression in a human colon tumor (HT29) xenograft model.

Discovery of the imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepine scaffold as a novel, potent and selective GABAA α5 inverse agonist series

Through iterative design cycles we have discovered a number of novel new classes where the imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepine was deemed the most promising GABAA α5 inverse agonist class with potential for cognitive enhanc

Tumor-inhibiting anellated azepinone derivatives

This invention relates to anellated azepinone derivatives, a method of their production, metal complexes of the anellated azepinone derivatives as well as their use in the treatment of tumor diseases.

LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS

The present invention provides novel compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

TUMOUR-INHIBITING ANNELLATED AZEPINONE DERIVATIVES

The invention relates to annellated azepinone derivatives, to a method for the production thereof, to metal complexes of the annellated azepinone derivatives, and to the use of the same for treating tumour diseases.

N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT

The present invention relates to the compound presented by formula (I) (wherein all symbols in formula (I) are the same mean as the description shown in the specification.), mitocondorial benzogeazepin receptor (MBR) antagonist comprising the compound, the preventive and/or treatment medicine against diseases caused by stress of which an active ingredient is the compound. Since the compound represented by formula (I) has MBR antagonistic activity, and controls the production of neurosteroid, it is useful as the preventive and/or treatment medicine against diseases caused by stress.

Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives

The present invention is a compound of formula wherein R1 is halogen or lower alkyl; R2 is hydrogen, lower alkyl, cycloalkyl, —(CH2)m-phenyl, wherein the phenyl ring may be substituted by lower alkoxy, or is —(CH2)m-indolyl; R3 is —C(O)O-lower alkyl, —C(O)OH, or a five membered heteroaromatic group, which rings may be substituted by lower alkyl or cycloalkyl; n is 0, 1 or 2; m is 0, 1 or 2; or a pharmaceutically acceptable acid addition salt thereof. Compound I shows high affinity and selectivity for GALA A α5 receptor binding sites.

Design and synthesis of 1,5- and 2,5-substituted tetrahydrobenzazepinones as novel potent and selective integrin αVβ3 antagonists

The design and synthesis of novel integrin αVβ3 antagonists based on a 1,5- or 2,5-substituted tetrahydrobenzaezpinone core is described. In vitro activity of respective compounds was determined via αVβ3 binding assay, and selected derivatives were submitted to further characterization in functional cellular assays. SAR was obtained by modification of the benzazepinone core, variation of the spacer linking guanidine moiety and core, and modification of the guanidine mimetic. These efforts led to the identification of novel αVβ3 inhibitors displaying potency in the subnanomolar range, selectivity versus αIIbβ3 and functional efficacy in relevant cellular assays. A method for the preparation of enantiomerically pure derivatives was developed, and respective enantiomers evaluated in vitro. Compounds 31 and 37 were assessed for metabolic stability, resorption in the Caco-2 assay and pharmacokinetics.